IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial

yf_tkr_AZN · 2026-10-24 · Bullish AI sentiment

$III $AZN

WILMINGTON, Del., October 24, 2026--Landmark results from the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgen’s tarlatamab-dlle demonstrated a statistically significant and highly clinically meaningful improvement in the primary endpoint of overall survival (OS) and in the key secondary endpoint of progression-free survival (PFS) versus IMFINZI alone as a 1st-line maintenance treatment. The trial included patients with extensive-stage small cell lung cancer (ES-SCLC) who had

Sector coverage: Technology · Information Technology Services · Healthcare · Drug Manufacturers - General

Read the original at yf_tkr_AZN ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.